TABLE I -ARTICLES MENTIONING DISSEMINATED CANCER CELL DETECTION BY RT-PCR IN CANCER PATIENTS: DISTRIBU-TION BY TYPE OF CANCER AND PERIOD OF TIME COV-ERED BY THE SEARCH

Type of cancer Number of articles and period covered
"mammaglobin". However, there are 2 different mammaglobins, and a PubMed search using the word "mammaglobin" does not retrieve all papers reporting on SCGB2A2 expression analysis. Another example of an "unpopular" gene symbol is KLK3, the HUGO symbol for the gene otherwise known as PSA (prostate-specific antigen). A PubMed search using KLK3 (without any other restriction) retrieves a total of only 53 articles published between 1994 and May 2008 (Tab. IV). For the same period, nearly 10,000 articles may be found using PSA as keyword. However, among these are only 27 of the 53 papers identified with KLK3. Thus, the use of multiple names for the same gene impairs the efficient retrieval of information from databases.
These observations support those of Tamames and Valencia (6) . These authors analyzed PubMed abstracts for the period 1994-2004, collecting information regarding the mention of human gene symbols and the frequency with which official symbols were mentioned in comparison with their aliases. From their study, it was obvious that the scientific community had not widely adopted the HUGO guidelines. Moreover, they observed that the proportion of official symbols that were used predominantly had only increased slightly, from 35% in 1994 to 44% in 2004. Thus, aliases were used far more often than official symbols. Examination of the data on a year-by-year basis indicated that the tendency to improve the situation by replacing aliases in favor of official HUGO symbols was weak. The changes in name usage, either from official to aliases or from aliases to official, were not very frequent, and the nomenclature of most genes remained rather stable with time.
The recourse to the HUGO gene nomenclature, notably in clinical studies, may increase significantly in the next years as a consequence of the introduction of microarrays and, more generally, bioinformatics in these studies. Indeed, the comparison of microarray data from different sources requires the exact mapping of the names used by different authors. This aim is generally achieved by mapping gene annotations obtained from different microarray platforms to the HUGO gene symbols and names. Many efforts are being made to standardize microarray data. This could ultimately render the HUGO names and symbols more "popular".
As reflected by the present article, the cancer community has not widely adopted the HUGO nomenclature. I suggest that the mention of standard names or symbols in abstracts in place of, or, at least, next to aliases, should be made mandatory. More generally, all actors of research should pay more attention to the usage of standard nomenclature. Indeed, the task of mentioning genes in papers by their official names and symbols will require the collaboration of authors and journals (editors and reviewers). Regarding journals, the pursuit of unique standard gene names and symbols has been encouraged for years by most journals primarily concerned with human genetics or molecular biology (some examples are American Journal of Human Genetics, Annals of Human Genetics, Biochemical Journal, Bioinformatics, Cancer Genomics and Proteomics, Cytogenetic and Genome Research, Genome Research, Genomics, Human Genetics, Human Mutation, Journal of Medical Genetics, Mammalian Genome, Molecular Therapy, Nature Reviews (all categories), Nucleic Acids Research, Pharmacogenetics and Genomics, PloS Genetics, The Journal of Immunology). In contrast, the frequency with which the HUGO nomenclature is used is still low in clinical journals that publish most of the data concerning tumor cell identification. The 303 articles examined in the present article were published in more than 100 journals (not Agreement on gene name usage will not only make one's own research easier, but will also be helpful to the present generation (as well as future generations) of researchers who are about to enter molecular clinical research. 
